CLINICAL TRIALS PROFILE FOR GEODON
✉ Email this page to a colleague
All Clinical Trials for GEODON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | Icahn School of Medicine at Mount Sinai | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00141271 ↗ | A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression | Completed | Pfizer | Phase 3 | 2005-07-01 | This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med. |
| NCT00141271 ↗ | A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 | 2005-07-01 | This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med. |
| NCT00208208 ↗ | Geodon (Ziprasidone) for Posttraumatic Stress Disorder | Completed | Pfizer | Phase 4 | 2002-12-01 | Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). |
| NCT00208208 ↗ | Geodon (Ziprasidone) for Posttraumatic Stress Disorder | Completed | Creighton University | Phase 4 | 2002-12-01 | Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GEODON
Condition Name
Clinical Trial Locations for GEODON
Trials by Country
Clinical Trial Progress for GEODON
Clinical Trial Phase
Clinical Trial Sponsors for GEODON
Sponsor Name
